Roche Holding AG (ROP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roche Holding AG (ROP) has a cash flow conversion efficiency ratio of 0.296x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF11.23 Billion ≈ $14.20 Billion USD) by net assets (CHF37.88 Billion ≈ $47.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Roche Holding AG market cap and net worth for the company's overall valuation and market capitalisation.
Roche Holding AG - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Roche Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Roche Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roche Holding AG ranked by their cash flow conversion efficiency. Explore earnings quality score of Roche Holding AG to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wells Fargo & Company
NYSE:WFC
|
0.051x |
|
AstraZeneca PLC
F:ZEGA
|
0.112x |
|
GE Vernova LLC
NYSE:GEV
|
0.344x |
|
Toyota Motor Corporation ADR
NYSE:TM
|
0.021x |
|
PetroChina Co Ltd Class A
SHG:601857
|
0.068x |
|
AstraZeneca PLC
NYSE:AZN
|
0.057x |
|
Texas Instruments Incorporated
NASDAQ:TXN
|
0.150x |
|
Westpac Banking Corporation
AU:WBCPI
|
-0.064x |
Annual Cash Flow Conversion Efficiency for Roche Holding AG (1998–2025)
The table below shows the annual cash flow conversion efficiency of Roche Holding AG from 1998 to 2025. View Roche Holding AG (ROP) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF37.88 Billion ≈ $47.89 Billion |
CHF17.83 Billion ≈ $22.54 Billion |
0.471x | -15.29% |
| 2024-12-31 | CHF36.16 Billion ≈ $45.72 Billion |
CHF20.09 Billion ≈ $25.40 Billion |
0.556x | +14.84% |
| 2023-12-31 | CHF33.26 Billion ≈ $42.05 Billion |
CHF16.09 Billion ≈ $20.35 Billion |
0.484x | -13.41% |
| 2022-12-31 | CHF32.02 Billion ≈ $40.48 Billion |
CHF17.89 Billion ≈ $22.62 Billion |
0.559x | -22.99% |
| 2021-12-31 | CHF28.34 Billion ≈ $35.84 Billion |
CHF20.57 Billion ≈ $26.00 Billion |
0.726x | +58.93% |
| 2020-12-31 | CHF39.77 Billion ≈ $50.28 Billion |
CHF18.16 Billion ≈ $22.96 Billion |
0.457x | -26.84% |
| 2019-12-31 | CHF35.87 Billion ≈ $45.35 Billion |
CHF22.39 Billion ≈ $28.30 Billion |
0.624x | -5.14% |
| 2018-12-31 | CHF30.37 Billion ≈ $38.39 Billion |
CHF19.98 Billion ≈ $25.26 Billion |
0.658x | +5.89% |
| 2017-12-31 | CHF29.01 Billion ≈ $36.67 Billion |
CHF18.02 Billion ≈ $22.79 Billion |
0.621x | +9.36% |
| 2016-12-31 | CHF26.40 Billion ≈ $33.38 Billion |
CHF15.00 Billion ≈ $18.97 Billion |
0.568x | -13.20% |
| 2015-12-31 | CHF23.30 Billion ≈ $29.46 Billion |
CHF15.25 Billion ≈ $19.28 Billion |
0.655x | -11.42% |
| 2014-12-31 | CHF21.56 Billion ≈ $27.26 Billion |
CHF15.93 Billion ≈ $20.14 Billion |
0.739x | -0.48% |
| 2013-12-31 | CHF21.24 Billion ≈ $26.85 Billion |
CHF15.77 Billion ≈ $19.94 Billion |
0.743x | -17.22% |
| 2012-12-31 | CHF16.73 Billion ≈ $21.15 Billion |
CHF15.01 Billion ≈ $18.97 Billion |
0.897x | +0.28% |
| 2011-12-31 | CHF14.48 Billion ≈ $18.31 Billion |
CHF12.95 Billion ≈ $16.38 Billion |
0.894x | -27.27% |
| 2010-12-31 | CHF11.66 Billion ≈ $14.74 Billion |
CHF14.34 Billion ≈ $18.13 Billion |
1.230x | -31.40% |
| 2009-12-31 | CHF9.41 Billion ≈ $11.90 Billion |
CHF16.88 Billion ≈ $21.34 Billion |
1.793x | +692.39% |
| 2008-12-31 | CHF53.82 Billion ≈ $68.05 Billion |
CHF12.18 Billion ≈ $15.40 Billion |
0.226x | +2.83% |
| 2007-12-31 | CHF53.31 Billion ≈ $67.39 Billion |
CHF11.73 Billion ≈ $14.83 Billion |
0.220x | -0.29% |
| 2006-12-31 | CHF46.81 Billion ≈ $59.19 Billion |
CHF10.33 Billion ≈ $13.06 Billion |
0.221x | -7.67% |
| 2005-12-31 | CHF41.74 Billion ≈ $52.77 Billion |
CHF9.97 Billion ≈ $12.61 Billion |
0.239x | +8.46% |
| 2004-12-31 | CHF33.29 Billion ≈ $42.09 Billion |
CHF7.33 Billion ≈ $9.27 Billion |
0.220x | -11.41% |
| 2003-12-31 | CHF29.16 Billion ≈ $36.87 Billion |
CHF7.25 Billion ≈ $9.17 Billion |
0.249x | +552.72% |
| 2002-12-31 | CHF25.77 Billion ≈ $32.58 Billion |
CHF982.00 Million ≈ $1.24 Billion |
0.038x | -74.64% |
| 2001-12-31 | CHF33.87 Billion ≈ $42.82 Billion |
CHF5.09 Billion ≈ $6.43 Billion |
0.150x | +22.90% |
| 2000-12-31 | CHF32.04 Billion ≈ $40.50 Billion |
CHF3.92 Billion ≈ $4.95 Billion |
0.122x | +112.35% |
| 1999-12-31 | CHF30.00 Billion ≈ $37.93 Billion |
CHF1.73 Billion ≈ $2.18 Billion |
0.058x | -63.69% |
| 1998-12-31 | CHF22.82 Billion ≈ $28.84 Billion |
CHF3.62 Billion ≈ $4.57 Billion |
0.159x | -- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more